Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia

Psychiatry Research

Volumn 109, Issue 3, 2002, Pages 297-302

  Zhang, Xiang Yang ^a,b,c   Zhou, Dong Feng ^a   Yuan, Cao Lian ^b   Zhang, Pei Yan ^b   Wu, Gui Ying ^b   Shen, Yu Cun ^a  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b BEIJING HUILONGGUAN HOSPITAL   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic drug; Dopamine; Haloperidol; Prolactin; Risperidone; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RADIOIMMUNOASSAY; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; CHRONIC DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0037090784     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(02)00022-7     Document Type: Article

References (34)

1. Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, Parkinsonian side effects, and neuroendocrine response
2. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug
3. Side effect profiles of new antipsychotic agents
4. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
5. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder
6. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: A multicentre double-blind comparative study
7. Neuropsychopharmacologic challenge in biological psychiatry
8. 5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to D-fenfluramine challenge in physically healthy human subjects
9. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
10. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia
11. Ritanserin attenuates anorectic, endocrine and thermic responses to D-fenfluramine in human volunteers
12. Hyperprolactinaemia in antipsychotic-treated patients: Guidelines for avoidance and management
13. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties
14. Clozapine: Plasma levels and prolactin response
15. 2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine
16. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
17. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
18. Effect of neuroleptic withdrawal on serum prolactin: A possible marker of receptor adaptation
19. Prolactin levels and adverse events in patients treated with risperidone
20. A study of serum prolactin levels in schizophrenia: Comparison of males and females
21. Biochemical profile of risperidone, a new antipsychotic
22. Risperidone in the treatment of schizophrenia
23. Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone
24. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses
25. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response
26. Melperone and clozapine: Neuroendocrine effects of atypical neuroleptic drugs
27. Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia
28. Atypical antipsychotics: Are some more atypical than others?
29. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
30. Dopamine receptors and the dopamine hypothesis of schizophrenia
31. Serum prolactin as a correlate of clinical response to haloperidol
32. Risperidone in treatment - Refractory schizophrenia
33. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication